AstraZeneca Pharma India Limited
AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.
What AstraZeneca files
- Others66
- Important50
- Updates36
- Board Meeting7
- Dividend/Bonus3
- Investor Meet3
AstraZeneca's Board has proposed a final dividend of Rs. 36 per share for FY25-26, pending shareholder approval. Tax will be deducted at source on this dividend, with rates varying based on shareholder residential status and documentation. Shareholders are advised to update their details by July 31 for accurate tax withholding.
AstraZeneca Pharma India ceased manufacturing in FY26, impacting all permanent workers. This shift led to substantial reductions in energy, water, GHG emissions, and waste. The company also notably increased local sourcing from MSMEs and neighboring districts.
AstraZeneca Pharma India's committee approved surrendering its factory license. This finalizes the company's previously announced exit from its manufacturing site and the surrender of its manufacturing license.
AstraZeneca Pharma India has announced that its Company Secretary, Ms. Manasa. R, has resigned to pursue external career opportunities. Her last day will be November 28, 2025. The company is actively searching for a suitable replacement for the position. **Issue:** A key management personnel change with the resignation of the...
AstraZeneca Pharma India announced its Company Secretary, Ms. Manasa R, has resigned, with her last day on Nov 28, 2025, to pursue other opportunities. This impacts a key corporate governance role. The company is actively searching for a suitable replacement. Investors will watch for a smooth transition to ensure continuous...